the aid library

LIST OPTIONS

Filter

4336

Sort by:

Direction:

Download (141)

View PDF (163)

National Action Plan of the Islamic Republic of Iran for combating antimicrobial resistance

Ministry of Health and Medical Education Iran (2016) C_WHO

Antimicrobial resistance is one of the most important threats to the health worldwide. Antimicrobial resistance or drug resistance is the reduction of the pharmaceutical effects of a drug against a disease or reduction of its effectiveness in improving the clinical signs of a disease. Antimicrobial ... more

Download (1375)

View PDF (1841)

Rotavirus: Common, Severe, Devastating, Preventable

The ROTA Council (2016) C1

Diarrhea is one of the world’s leading causes of child illness and death, and rotavirus is the most common cause of severe diarrhea. Yet it can be prevented and treated. There is a vaccine. And while hundreds of thousands of children in India will gain access to rotavirus vaccines -part of a natio... more

Download (96)

View PDF (112)

Human Resources for Health in Ethiopia

The Collaborative Africa Budget Reform Initiative (CABRI) (2016) C1

Ethiopia has seen high economic growth over the last decade, but remains a poor country with a high burden of disease. It has made considerable health gains in recent years, mainly by having health policies that focus on extending primary healthcare, using health extension workers. It... more

Download (898)

View PDF (2616)

Ebola Response in Liberia: Community health volunteers

Hiemstra, Nienke Oxfam (2015)

When Ebola hit Liberia in 2014, an atmosphere of fear and confusion contributed to the spread of the virus by making people unwilling to come forward for testing and treatment. Oxfam trained and equipped community health volunteers to go door-to-door, giving information and advice, encouraging anyon... more

Download (587)

View PDF (1194)

Recovering from the Ebola Crisis

Magdy Martínez-Solimán; Abdoulaye Mar Dieye; Izumi Nakamitsu et al. United Nations, The World Bank, European Union and African Development Bank (2015)

Full Report. In response to a call by the United Nations Secretary-General and the Governments of Guinea, Liberia and Sierra Leone, an international team conducted an Ebola Recovery Assessment. The aim was to contribute towards laying the foundation for short-, medium- and long-term recovery while ... more

Download (125)

View PDF (805)

Introducing One Health to the ethical debate about zoonontic diseases in Southeast Asia

Capps, B.; M.M. Bailey, D. Bickford et al. Bioethics (2015) CC

Bioethics 519 (online) doi:10.1111/bioe.12145 Volume 29 Number 8 2015 pp. 488–596; Pandemic plans recommend phases of response to an emergent infectious disease (EID) outbreak, and are primarily aimed at preventing and mitigating human-to-human transmission. These plans carry presumptive weight ... more

Download (507)

View PDF (715)

Waterborne Outbreaks of Hepatitis E: recognition, investigation and control

World Health Organization (WHO) (2014) C_WHO

Technical report
This manual aims to provide information about the methods for investigating outbreaks of hepatitis E, and measures for their prevention and control. In addition, the manual gives information about the causative agent – known as the hepatitis E virus (HEV) – its epidemiology... more

Download (196)

View PDF (447)

Collecting Data on Chid Disability. Companion Technical Booklet

UN Children's Fund UNICEF (2014)

Webinar. The purpose of this booklet is to help readers understand why data on children with disabilities are currently inadequate, the difficulties that surround the gathering of high-quality data on disabled children, and why there is a real need to improve the collection, analysis, dissemination... more

Download (930)

View PDF (1990)

Technical update on treatment optimization: use of efavirenz during pregnancy: a public health perspective

World Health Organization (2012) C_WHO

1.HIV infections – drug therapy. 2.Anti-HIV agents – adverse effects. 3.Anti-retroviral agents. 4.Benzoxazines – adverse effects. 5.Pregnancy. 6.Disease transmission, Vertical - prevention and control. 7.Treatment outcome. I.World Health Organization

Download (101)

View PDF (132)

Impacto socioeconómico de la tuberculosis en el Perú 2010

Ministerio de Salud, Peru (2012) CC

La publicación evalúa en forma cuantitativa y cualitativa el costo socioeconómico de la tuberculosis en el Perú con la finalidad de mejorar la comprensión real de gasto social y costo que representa para las personas, familias y Estado peruano. Asimismo, desarrolla bajo el marco del Objetivo 4 ... more

Download (911)

View PDF (1654)

Atlas of Health and Climate

World Health Organization WHO Word Health Organization (2012) C_WHO

The Atlas of health and climate is a product of this unique collaboration between the meteorological and public health communities. It provides sound scientific information on the connections between weather and climate and major health challenges. These range from diseases of poverty to emergencies... more

Download (99)

View PDF (686)

Q&A: Antibiotic resistance: where does it come from and what can we do about it?

Wright G.D. BMC Biology (2010) C2

Historically, the discovery of the sulfa drugs in the 1930s and the subsequent development of penicillin during World War II ushered in a new era in the treatment of infectious diseases. Infections that were common causes of death and disease in the pre-... more

Download (128)

View PDF (175)

Populorum Progressio Encyclical of POPE PAUL VI on the development of peoples

Holy Father Paul VI Libreria Editrice Vaticana (1967) C2

The progressive development of peoples is an object of deep interest and concern to the Church. This is particularly true in the case of those peoples who are trying to escape the ravages of hunger, poverty, endemic disease and ignorance; of those who are seeking a larger share in the benefits of ci... more

Download (25)

View PDF (64)

Hearts - D: Diagnosis and Management of Type 2 Diabetes 2020

World Health Organization WHO; International Diabetes Federation (2020) C_WHO

Diabetes mellitus, commonly known as diabetes, is a group of metabolic disorders characterized by the presence of hyperglycaemia in the absence of treatment. The heterogeneous aetiopathology includes defects in insulin secretion, insulin action, or both. The long-term specific complications of diabe... more

Download (498)

View PDF (903)

State of Health in the WHO African Region
recommended

World Health Organization WHO, Regional Office African Region (2018) C_WHO

This report is not a country scorecard. Rather, its purpose is to act as a compass to guide progress towards health in the SDGs. There has been a significant improvement in the state of health in the region with healthy life expectancy - time spent in full health - in the region increasing from 50... more

Download (133)

View PDF (193)

Inheriting a sustainable world? Atlas on children’s health and environment.

World Health Organization (WHO) (2018) C_WHO

In 2015, 26% of the deaths of 5.9 million children who died before reaching their fifth birthday could have been prevented through addressing environmental risks – a shocking missed opportunity. The prenatal and early childhood period represents a window of particular vulnerability, where enviro... more

Download (126)

View PDF (154)

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015(2016 interim update)

British HIV Association (2016) CC

The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ... more

Download (44)

View PDF (47)

Guidelines for Management of Type 1 Diabetes

Indian Council of Medical Research (2022) CC2

The ICMR type 1 diabetes guidelines come at a time when the SARS-CoV-2 pandemic has disproportionately affected people with diabetes population, exposing them to a high risk for severe illness and mortality. Globally, diabetes was responsible for over fourmillion deaths in the year 2019. It was th... more

Download (274)

View PDF (370)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (220)

View PDF (207)

Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region

World Health Organization WHO WHO Regional Office for the Eastern Mediterranean (2014) CC

This publication represents a key step forward in translating Control of the leishmaniases (WHO Technical Report Series, No. 949) into a more practical tool for health personnel directly involved in the case management of cutaneous leishmaniasis. With this manual, countries will have, for the first ... more

State of Health in the WHO African Region recommended

State of Health in the WHO African Region
recommended